摘要
糖尿病的患病率居高不下,现代人们久坐不动的生活方式也导致了超重和肥胖人群的增多。虽然我们对血糖升高继发的各种并发症已经有了更深入的认识,但药物种类的繁多以及患者长期治疗依从性的下降也给临床治疗增添了几分难度。胰高血糖素样肽-1受体激动剂的问世似乎给体型肥胖的2型糖尿病患者带来了曙光。作为一款降糖药,它不仅可以有效避免低血糖的发生,还可以降低体质指数。近年来,人们还发现了GLP-1受体激动剂的一些非降糖作用,如保护患者的肝脏、肾脏和心血管等系统,降低或延缓相应并发症的发生及发展,甚至可以用于治疗帕金森病和阿尔茨海默症等疾病。本文通过GLP-1受体激动剂在生物及临床研究中的进展展开讨论,探讨其在临床使用中的价值。
The prevalence rate of diabetes is high, and the change of modern people’s lifestyle has also led to an increase in overweight and obese people. Although we have a deeper understanding of various complications secondary to elevated blood glucose, the wide variety of drugs and the decline of patients’ long-term treatment compliance also add some difficulties to clinical treatment. The advent of glucagon like peptide-1 receptor agonist seems to bring dawn to obese patients with type 2 diabetes. As a hypoglycemic drug, it can not only effectively avoid hypoglycemia, but also reduce body mass index. In recent years, some non-hypoglycemic effects of GLP-1 receptor agonists have also been found, such as protecting patients’ liver, kidney and cardiovascular systems, reducing or delaying the occurrence and development of corresponding complications, and even can be used to treat diseases such as Parkinson’s disease and Alzheimer’s disease. This paper discusses the progress of GLP-1 receptor agonist in biological and clinical research, and discusses its value in clinical use.
出处
《临床医学进展》
2022年第4期2979-2988,共10页
Advances in Clinical Medicine
